ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.
about
Potential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate CancerClinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancerEmerging PSA-based tests to improve screeningComprehensive assessment for novel prostate cancer markers in the prostate-specific antigen era: focusing on Asians and Asian countriesClinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literatureProstate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/mlThe prostate health index selectively identifies clinically significant prostate cancer.PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer.Imaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical OverviewDifferentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics.Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.Novel biomarkers for the detection of prostate cancer.Nuclear morphometry, nucleomics and prostate cancer progressionFrom prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer.Implementation of PSA-based active surveillance in prostate cancer.Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS).Prostate cancer risk variants are not associated with disease progression.Predicting Pathological Features at Radical Prostatectomy in Patients with Prostate Cancer Eligible for Active Surveillance by Multiparametric Magnetic Resonance Imaging.Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study.
P2860
Q26784517-2AA87A5F-2FE8-49DE-A2C2-B454AE9DBAFEQ26824913-FA69A8CF-E8DE-4CED-AB57-DA3490FB03C7Q26828563-25B42C2D-4A47-462A-8FC3-90AA2DE1E9C8Q26996461-2F027593-AD37-4677-B5B2-5AA79A2F293BQ33911725-1DFFBA0E-B579-4350-83E8-82552CD495C8Q34825819-904E7A99-5F3F-41A9-AC17-0B2406C1C930Q35498981-3FB37312-D805-457F-96DA-1A7BAF2FDAF3Q35993261-CC4CC0BC-D66B-4E18-9B17-BE8A9ACD0966Q36979944-23D4B80B-4054-456B-A465-45195D9B15E5Q37037804-4628B04D-B3E4-492C-8456-0F0631C142C8Q37685652-FEB564E5-6D71-4062-BD09-7B5603384602Q37708174-74445965-1190-4FEE-A9B8-0C31ACFBA804Q38002780-468B1CF9-93F4-45C3-B552-EFC07E3738D4Q38023597-866A290C-4885-4FC6-9036-59D8EEC903A2Q38239830-A31D84B9-A361-4C46-AB73-513D58A55682Q39023692-DEC19845-6C18-46E6-9E3D-EB35B3DAC2CAQ39757112-C480E5F4-9FEB-42D5-8FD4-93F3DA2FD250Q40458086-B0FA203B-5C5C-4380-8809-D6174462B983Q46632925-BDE8830A-A778-427C-BE0A-96B4273587F4Q52679257-FED51EC9-B153-4D8F-B0BE-BCB0B8D1C5F3
P2860
ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
ProPSA and diagnostic biopsy t ...... n active surveillance program.
@ast
ProPSA and diagnostic biopsy t ...... n active surveillance program.
@en
type
label
ProPSA and diagnostic biopsy t ...... n active surveillance program.
@ast
ProPSA and diagnostic biopsy t ...... n active surveillance program.
@en
prefLabel
ProPSA and diagnostic biopsy t ...... n active surveillance program.
@ast
ProPSA and diagnostic biopsy t ...... n active surveillance program.
@en
P2093
P2860
P1433
P1476
ProPSA and diagnostic biopsy t ...... n active surveillance program.
@en
P2093
Cameron Marlow
Danil V Makarov
H Ballentine Carter
Jonathan I Epstein
Lori J Sokoll
Patricia Landis
Robert W Veltri
Sumit Isharwal
P2860
P304
P356
10.1016/J.UROLOGY.2010.07.526
P407
P577
2011-01-08T00:00:00Z